Polymorphs of ponatinib hydrochloride

US10221184B2 · kind B2 · utility

Assignee

• Apicore US LLC · US

Inventors

• Ravishanker Kovi · Sparta, US
• Jayaraman Kannapan · Sayla, IN
• Ananda Babu Thirunavakarasu · Sayla, IN
• Gaurav Yadav · Sidhauli, IN
• Veerabhadra Rao Bobbili · Darsi, IN
• Shivnath Sahebrao Patil · Dhule, IN
• Sanjay F. Thakor · Sayla, IN

Key dates

• Filing date: Jan 4, 2018
• Grant date: Mar 5, 2019
• Expiry date: Jan 4, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Chemical engineering
• WIPO sector: Chemistry

Abstract

Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 1; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 3; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.